iBio Inc.

Partners

iBio establishes partnerships through product collaborations and platform licensing arrangements.

Partners

Types of Collaborations

The iBio Technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.

Products

Products

Out-licensing products produced with the iBio Technology platform

Partnerships

Partnerships

Partnering iBio™'s technology for exploratory, research or validation studies

Platform

Platform

Out-licensing the iBio Technology platform for the production of biotherapeutics and vaccines

Partnership Projects

iBio's business strategy is to broadly participate in the markets that the iBio Technology platform addresses.
Current partner projects include:

iBio Technology Partner

Market

Product

Status

Oswaldo Cruz Foundation
Oswaldo Cruz Foundation
Viral Disease Vaccines
Yellow Fever
Animal efficacy demonstrated
DoD (DARPA)
DoD (DARPA)
Viral Disease Vaccines
H5N1 and H1N1 Influenza
Completed Phase 1 clinical trials
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Viral Disease Vaccines
H5N1 and H1N1 Influenza
Completed Phase 1 clinical trials
GE Healthcare
GE Healthcare
Facility Design
Facility Design
Conceptual & Basic Design Completed
National Institutes of Health
National Institutes of Health
Bacterial Disease Infection
Anthrax
IND submitted
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Parasitic Pathogen Vaccine
Malaria
Phase 1 underway
Sabin Institute
Sabin Institute
Parasite Vaccines
Hookworm
Phase 1 underway
Medical University of South Carolina
Fibrotic Disease
iBio CFB03
Preclinical

GE Healthcare

Global Business Development Alliance Formed in 2012

  • iBio and GE jointly market the strengths of iBio™s superior biologics manufacturing platform with the expertise and proprietary downstream products of GE
  • iBio™s research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), will continue to play a key role in advancing the iBio Technology platform

We're delighted to form this new global alliance with iBio, who share our vision of bringing affordable and flexible manufacturing capabilities to the producers of these vital, lifesaving medicines.

We look forward to continuing our work with the talented teams at iBio and CMB to explore how this innovative technology could become a commercial reality.

Oliver Loeillot
General Manager of Enterprise Solutions

Learn More About Partnerships

iBio is establishing partnerships through iBio Technology platform licensing arrangements and product collaborations.

Interested in Becoming a Partner?

iBio Technology

The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Learn more